Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo

Frede, Annika; Neuhaus, Bernhard; Klopfleisch, Robert; Walker, Catherine; Buer, Jan; Müller, Werner; Epple, Matthias; Westendorf, Astrid M.

doi:10.1016/j.jconrel.2015.12.021

Cited by 107 publications

(60 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, multi-shell CaP nanoparticles (CaP-siRNA) encapsulated into poly(D,Llactide-co-glycolide) (PLGA) and a final layer of polyethyleneimine (PEI) for the local therapeutic treatment of colonic inflammation [51]. The synthesis of nanoparticles was performed via rapid mixing of equal amounts of calcium-L-lactate and diammonium hydrogen phosphate aqueous solutions.…”

Section: The Use Of Calcium Phosphate Nanoparticles For In Vivo Gene mentioning

confidence: 99%

Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and Recent Applications

Bakan¹

2018

Hydroxyapatite - Advances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets

View full text Add to dashboard Cite

Gene therapy is a targeted therapy which can be used in the treatment of various acquired and inherited diseases. Inhabitation of a gene function, restoring or improving a gene, or gaining a new function can be achieved by gene therapy strategies. The most crucial step in this therapy is delivering the therapeutic material to the target. Nanosized calcium phosphates (CaPs) have been considered as promising carriers due to their excellent biocompatibility. In this chapter, the delivery of DNA, siRNA, and miRNA by using CaP nanocarriers were compiled in detail and the main parameters which can affect the carrier properties and thus the gene transfer efficiency were also discussed.

show abstract

Section: The Use Of Calcium Phosphate Nanoparticles For In Vivo Gene mentioning

confidence: 99%

Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and Recent Applications

Bakan¹

2018

Hydroxyapatite - Advances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets

View full text Add to dashboard Cite

show abstract

“…[13][14][15] The viral carriers are limited by their lower cargo loading capacity and safety problems related to immune reactions. 16 In this context, non-viral carriers have gained more attention in siRNA delivery for cancer therapy; several non-viral vectors, including cationic lipids, gold nanoparticles, phosphatidylethanolamine, silica nanoparticles, polyethylenimine, polypeptides, poly(lactideco-glycolide), and chitosan (CS) have been successfully investigated for siRNA delivery. [16][17][18][19][20] CS is a common non-viral vector for siRNA delivery.…”

Section: Sun Et Almentioning

confidence: 99%

“…16 In this context, non-viral carriers have gained more attention in siRNA delivery for cancer therapy; several non-viral vectors, including cationic lipids, gold nanoparticles, phosphatidylethanolamine, silica nanoparticles, polyethylenimine, polypeptides, poly(lactideco-glycolide), and chitosan (CS) have been successfully investigated for siRNA delivery. [16][17][18][19][20] CS is a common non-viral vector for siRNA delivery. CS as siRNA delivery carrier has many advantages such as it is nontoxic, nonimmunogenic, biodegradable, and biocompatible.…”

Section: Sun Et Almentioning

confidence: 99%

Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis

Park¹,

Huang

Jin³

et al. 2016

IJN

View full text Add to dashboard Cite

Nanoparticle-mediated small interfering RNA (siRNA) delivery is a promising therapeutic strategy in various cancers. However, it is difficult to deliver degradative siRNA to tumor tissue, and thus a safe and efficient vector for siRNA delivery is essential for cancer therapy. In this study, poly(ethylene glycol)-modified chitosan (PEG-CS) was synthesized successfully for delivering nucleic acid drug. We deemed that PEGylated CS could improve its solubility by forming a stable siRNA loaded in nanoparticles, and enhancing transfection efficiency of siRNA-loaded CS nanoparticles in cancer cell line. The research results showed that siRNA loaded in PEGylated CS (PEG-CS/siRNA) nanoparticles with smaller particle size had superior structural stability in the physical environment compared to CS nanoparticles. The data of in vitro antitumor activity revealed that 4T1 tumor cell growth was significantly inhibited and cellular uptake of PEG-CS/siRNA nanoparticles in 4T1 cells was dramatically enhanced compared to naked siRNA groups. The results from flow cytometry and confocal laser scanning microscopy showed that PEG-CS/siRNA nanoparticles were more easily taken up than naked siRNA. Importantly, PEG-CS/siRNA nanoparticles significantly reduced the growth of xenograft tumors of 4T1 cells in vivo. It has been demonstrated that the PEG-CS is a safe and efficient vector for siRNA delivery, and it can effectively reduce tumor growth and prevent metastasis.

show abstract

“…The results suggested that the expression of TNF-α mRNA decreased 40% and the expression of KC and IP-10 decreased 50% in the colon tissue compared to the controls after siRNA-loaded CaP-PLGA nanoparticle treatment. 72 To locate the position of nanoparticles in mice, an in vivo imaging system was applied. BALB/c mice were intrarectally injected with AlexaFluor750-oligonucleotide CaP/PLGA nanoparticles (50 µg siRNA) after fasting overnight.…”

mentioning

confidence: 99%

“…Similarly, enhanced nanoparticle uptake was observed in a colonic inflammatory model compared to healthy conditions. 65,72 Ali et al 77 administered identical doses of FITC-labeled budesonide-PLGA nanoparticles by gavage to mice under colonic inflamed and healthy conditions. The nanoparticle localization in colon tissue was determined using an in vivo imaging system.…”

mentioning

confidence: 99%

RNA interference-based nanosystems for inflammatory bowel disease therapy

Guo¹,

Jiang²,

Gui³

2016

IJN

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, recrudescent disease that invades the gastrointestinal tract, and it requires surgery or lifelong medicinal therapy. The conventional medicinal therapies for IBD, such as anti-inflammatories, glucocorticoids, and immunosuppressants, are limited because of their systemic adverse effects and toxicity during long-term treatment. RNA interference (RNAi) precisely regulates susceptibility genes to decrease the expression of proinflammatory cytokines related to IBD, which effectively alleviates IBD progression and promotes intestinal mucosa recovery. RNAi molecules generally include short interfering RNA (siRNA) and microRNA (miRNA). However, naked RNA tends to degrade in vivo as a consequence of endogenous ribonucleases and pH variations. Furthermore, RNAi treatment may cause unintended off-target effects and immunostimulation. Therefore, nanovectors of siRNA and miRNA were introduced to circumvent these obstacles. Herein, we introduce non-viral nanosystems of RNAi molecules and discuss these systems in detail. Additionally, the delivery barriers and challenges associated with RNAi molecules will be discussed from the perspectives of developing efficient delivery systems and potential clinical use.

show abstract

Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo

Cited by 107 publications

References 72 publications

Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and Recent Applications

Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and Recent Applications

Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis

RNA interference-based nanosystems for inflammatory bowel disease therapy

Contact Info

Product

Resources

About